NCT07339176: Intratumoral N17350 in Advanced Solid Tumors
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 275 planned
- Started
- 25 May 2026
- Primary completion
- Jul 2028
- Arms
- N17350 Intratumoral Injection 1 mg/ml superficial lesions, N17350 Intratumoral Injection 2 mg/ml superficial lesions, N17350 Intratumoral Injection 4 mg/ml superficial lesions, N17350 Intratumoral Injection 2 mg/ml visceral lesions, N17350 Intratumoral Injection 4 mg/ml visceral lesions, N17350 Intratumoral Injection for cuSCC, N17350 Intratumoral Injection for Melanoma, N17350 Intratumoral Injection for SCCHN, N17350 Intratumoral Injection for NSCLC, N17350 Intratumoral Injection for TNBC
- Results
- None posted
- 14 Jan 2026: Trial registered
- 25 May 2026: Trial started